Next Article in Journal
Systemic Antibiotics and Obesity: Analyses from a Population-Based Cohort
Next Article in Special Issue
Mid-Phase Hyperfluorescent Plaques Seen on Indocyanine Green Angiography in Patients with Central Serous Chorioretinopathy
Previous Article in Journal
Is It the Surgeon, the Patient, or the Device? A Comprehensive Clinical and Radiological Evaluation of Factors Influencing Patient Satisfaction in 648 Total Knee Arthroplasties
Previous Article in Special Issue
The COVID-19 Pandemic Has Had Negative Effects on Baseline Clinical Presentation and Outcomes of Patients with Newly Diagnosed Treatment-Naïve Exudative AMD
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 10
Issue 12
10.3390/jcm10122600
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

High Myopia and the Complement System: Factor H in Myopic Maculopathy

by
Enrique García-Gen
1,
Mariola Penadés
1,2,
Salvador Mérida
1,
Carmen Desco
1,3,
Rafael Araujo-Miranda
3,
Amparo Navea
1,2 and
F. Bosch-Morell
1,2,3,*
1
Departamento Ciencias Biomédicas, Universidad CEU Cardenal Herrera, CEU Universities, 46115 Valencia, Spain
2
Thematic Cooperative Health Network for Research in Ophthalmology (Oftared), Carlos II Health Institute, 28029 Madrid, Spain
3
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), 46020 València, Spain
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2021, 10(12), 2600; https://doi.org/10.3390/jcm10122600
Submission received: 4 May 2021 / Revised: 6 June 2021 / Accepted: 7 June 2021 / Published: 12 June 2021
(This article belongs to the Special Issue New Advances in Retinal Research)
Browse Figures
Review Reports Versions Notes

Abstract

:
High myopia (HM) is both a medical problem and refractive error of the eye owing to excessive eyeball length, which progressively makes eye tissue atrophic, and is one of the main causes for diminishing visual acuity in developed countries. Despite its high prevalence and many genetic and proteomic studies, no molecular pattern exists that explain the degenerative process underlying HM, which predisposes patients to other diseases like glaucoma, cataracts, retinal detachment and chorioretinal atrophy that affect the macular area. To determine the relation between complement Factors H (CFH) and D (CFD) and the maculopathy of patients with degenerative myopia, we studied aqueous humor samples that were collected by aspiration from 122 patients during cataract surgery. Eyes were classified according to eyeball axial length as high myopia (axial length > 26 mm), low myopia (axial length 23.5–25.9 mm) and control (axial length ˂ 23.4 mm). The degree of maculopathy was classified according to fundus oculi findings following IMI’s classification. Subfoveal choroid thickness was measured by optical coherence tomography. CFH and CFD measurements were taken by ELISA. CFH levels were significantly high in the high myopia group vs. the low myopia and control groups (p ˂ 0.05). Significantly high CFH values were found in those eyes with choroid atrophy and neovascularization (p ˂ 0.05). In parallel, the CFH concentration correlated inversely with choroid thickness (R = −0.624). CFD levels did not correlate with maculopathy. All the obtained data seem to suggest that CFH plays a key role in myopic pathology.

1. Introduction

High myopia (HM) is both a medical problem and refractive error of the eye owing to excessive eyeball length, which progressively makes eye tissue atrophic, and is one of the main causes of diminishing visual acuity in developed countries [1,2]. High myopia prevalence is expected to rise in forthcoming years and to affect 938 million people by 2050, which makes it a first-order disease of clinical interest [3,4,5,6,7]. Despite its high prevalence and many genetic and proteomic studies, no molecular pattern exists that explains the degenerative process underlying HM, which predisposes patients to other diseases like glaucoma, cataracts, retinal detachment and chorioretinal atrophy [8,9,10,11].
High myopia can lead to blindness when severe chorioretinal atrophy develops. Another common ocular disease that can cause severe vision loss, is the final form of dry age-related macular degeneration (ARMD) called geographic atrophy. This ARMD variant comes with progressive choroid atrophy, followed by retinal atrophy and loss of vision. Although the two diseases do not seem to have the same ethiopathogenesis, to a certain extent, this is a similar process to progressive chorioretinal atrophy, which is typical of HM [12,13,14]. Alterations to complement factor H (CFH) and complement factor D (CFD) have been related to both conditions, ARMD and geographic atrophy. Former studies have evaluated how the complement system is involved in ARMD (age-related macular degeneration) and demonstrated how the association of the genes of the alternative pathway of the complement system, especially those involved in CFH and CFD, is more susceptible to ARMD [15,16,17,18,19]. The complement system is a critical component of the innate immunity responsible for the opsonization and removal of bacterial and apoptotic cell remains, and also for recruiting immune cells at infection sites and in tissue damage [20,21]. Its activation is triggered by several mechanisms depending on the involved pathway (classic, alternative and lectins). They all converge to form C3 convertase, which results in the formation of products C3a, C3b and C5a, and the C5b-9 membrane attack complex [20,21]. The efficiency of its functioning depends on the fine control of its activation. When it is deregulated or overactivated, it can perform homeostatic and pathological functions by driving different inflammatory disorders, which reflect the complement’s multifaceted nature [18,22].
Animal models have been valuable in investigating the mechanisms involved in the development of myopia. Numerous studies have shown that degradation of the visual input using form deprivation or lens defocus can induce axial myopia during the early postnatal period [23,24]. During this process, the retina is thought to initiate signal transduction triggered by blurred vision. The findings described in animal models suggest that both complement activation and inflammation plays a crucial role in the development of myopia. Moreover, the results provide novel evidence for transcriptional activation of the complement system during both myopia and hyperopia induction, and confirm existing literature implicating cell signaling, mitochondrial, and structural processes in refractive error. Further comparisons demonstrated association and extensive similarities in genes linked to age-related macular degeneration, choroidal neovascularization and cataract [15,25,26,27,28].
Nonetheless, the role played by the complement has not been studied to date in patients with HM and chorioretinal atrophy, although such knowledge may be very important for acquiring in-depth information about this pathology. So we have studied complement H and D factors in high myopic eyes in order to identify changes related to the presence or not of atrophy.

2. Materials and Methods

We conducted a cross-sectional research study by selecting 122 eyes of patients who were being operated for cataracts at the FISABIO Medical Ophthalmological Clinic in Valencia (Spain) to analyze complement Factors H and D in the aqueous humor of myopic and control eyes. The inclusion criteria were: patients with cataracts ready to be operated, refractive hypermetropia defects and astigmatism below +0.75D and 1.75D, respectively. The exclusion criteria were: concomitant eye disease that could interfere with the results (ongoing maculopathy other than myopic maculopathy, uncontrolled glaucoma with two topical drugs, any stage of uveitis, venous or retinal arterial occlusions, hypermetropia refraction over +2D, astigmatism over 3D). All the participants in this study were Caucasian. They presented cataract eyes with nuclear color and opalescence, cortical or posterior subcapsular cataract 2–3, according to the Lens Opacities Classification System III. Uncontrolled high blood pressure with treatment, diabetes, high cholesterol index with treatment were considered the exclusion criterion.
Experimental groups were formed according to eyeball axial length. Any eyes whose axial length exceeded 26 mm were classified as HM; axial lengths between 23.5 and 25.9 mm were classified as low myopia (LM); axial lengths below 23.4 mm were employed as the control group. As all the patients had cataracts, refractive status was not used to classify our patients in order to avoid any bias caused by index myopia [29].
This study was approved by the FISABIO Ethics and Clinical Research Committee, and the whole study complied with the Declaration of Helsinki. All the patients gave informed consent and underwent complete ophthalmological examination, including: ETDRS best-corrected visual acuity (BCVA); exploring the anterior segment by a slit-lamp; binocular ophthalmoscopy and wide-field retinography using Optos® Optomap® P200Tx to study fundus oculi; detecting detect presence or not of staphyloma; classifying maculopathy according to International Myopia Institute (IMI’s classification) [30]. The axial length measurements were taken by interferometry (Zeiss IOLMaster 700®) and optical coherence tomography (Swept-source optic coherence tomography SSOCT TOPCON, Tokyo, Japan) to obtain the choroidal thickness measurement. This measurement was manually taken with a measuring instrument (caliper) facilitated by the software that came with the apparatus. Measurements were performed by two different observers (CDE and RAM) masked for the axial length of the patient. Sections where foveal depression was well observed were selected, a measurement was made per patient and observer (two measurements for eye in total) at the point corresponding to the center of the fovea. The concordance rate was 95% between them.
Aqueous humor samples were collected during cataract surgery. After sterilizing eyelids and eyelashes, and instilling 5% iodine povidone on the conjunctival sac, a sterile adhesive dressing was placed to separate lashes. The eye surface was washed with saline solution, and paracentesis was performed at the site where the surgical incision was to be made using a 30 G needle to aspire an aqueous humor sample of 120 μL inside a 1cc syringe. Then surgery commenced following the standard technique. The sample hence collected was placed inside an eppendorf tube to be frozen in liquid nitrogen to be kept at −80 °C until it was used.
The complement Factors H and D measurements were taken following the optimized protocol of the Human Adipsin ELISA Kit (catalog number: CSB-E14369h) and the Cusabio Human Complement Factor H ELISA Kit (catalog number: CSB-E08931h) (Cusabio Technology, Houston, TX 77054, USA). Statistical analyses were performed with version 24.0 of the commercially available IBM SPSS software (IBM Corp. 2016 for Windows, Version 24.0, Armonk, NY: IBM Corp., USA) and version 7.04 of GraphPad Prism for Windows (GraphPad Software, La Jolla, CA, USA). Data normality was verified by the Kolmogorv-Smirnov test (p > 0.05). The ANOVA of the data found by Levene’s test was performed by Tukey’s test as a post hoc analysis, provided that the homogeneity of variances was indicated (p ˂ 0.05). For those variables that did not present homogeneity of variances, the Kruskal-Wallis test was used as a non-parametric analysis. Pearson’s or Spearman’s correlations were employed to examine the strength of the association between two variables. The values of axial length, choroidal thickness and age were tested in a stepwise multiple linear regression to predict the Factor H and determine their individual effect on it. Statistical significance was set at p ˂ 0.05. Values are expressed as mean ± SD.

3. Results

The 122 patients were distributed as follows: 43 were the controls, 47 were LM and 32 were HM. Their mean age was 75.6 ± 6.9, 73.4 ± 10.3 and 66.4 ± 12.5 years, respectively, with 57% women and 43% men. Choroid thicknesses, as measured by optical coherence tomography, notably reduced in the HM group (128.4 ± 101.3 μm) compared to the control (237.1 ± 64.0 μm) and LM (199.2 ± 78.0 μm) groups, for whom significance was 0.01 (Table 1). There are no significant differences between both sexes, so the patients are treated as a single group.
To analyze the developed pathologies in our studied patients, IMI´s classification was followed with five degrees of macular degeneration (Table 2). In 93.75% of the control patients, eyes looked normal, with tessellation in 6.25% of cases. Macular degeneration predominated more in the HM group, along with diffuse chorioretinal atrophy, lacquer cracks and macular atrophy in 85.18% of cases (Table 2).
The analysis of CFH and CFD reflected significantly high mean concentrations (p ˂ 0.05) for CFH in the HM group (27.19 ± 15.47 ng/mL) compared to the LM (22.91 ± 10.52 ng/mL) and control (22.76 ± 5.90 ng/mL) groups (Figure 1a). The mean CFH values rose as eyeball axial lengths increased (Figure 1c) at the same time as this axial elongation reduced choroid thickness (Figure 1d). The mean CFD concentration obtained in the HM group (50.73 ± 12.62 ng/mL) was slightly lower than in the LM (53.20 ± 20.75 ng/mL) and control (52.81 ± 19.87 ng/mL) groups, with no significant differences (Figure 1b; p > 0.05).
In accordance with the degree of developed maculopathy in patients, the choroid thickness analysis indicated a significant reduction in choroid thickness in the patients who presented lacquer cracks and neovascularization compared to the eyes that looked normal (Figure 2a). Axial length significantly increased in the patients showing lacquer cracks, choroidal atrophy and neovascularization in relation to the eyes that looked normal (p ˂ 0.05; Figure 2b). The Spearman’s correlation analysis performed between choroid thickness and CFH levels indicated a level of significance of p ˂ 0.05, and CFH correlated inversely with choroid thickness (R= −0.624) (Figure 2c). Complement Factor H presented higher levels as myopic maculopathy developed, and both macular atrophy and neovascularization significantly increased compared to the eyes that looked normal (p ˂ 0.05) (Figure 2d).
We further found that both axial length and choroidal thickness were the factors associated with Factor H (β = −0.374, p < 0.001 and β = 0.253, p = 0.016, respectively), in the multiple regression model (p < 0.05). In this model, the contribution of age variable was insignificant (β = −0.048, p = 0.627).

4. Discussion

Interest in the complement system has recently reappeared after its involvement in AMD has been discovered [14,22,31,32]. Among the factors that regulate the alternative pathway, we find Factor H, synthesized in the eye by the optic nerve, the sclera, the retinal pigment epithelium, the retina, the ciliary epithelium and the crystalline lens [33]. It inactivates Factor C3b directly to prevent cascade amplification.
High myopia and developing myopic maculopathy are associated with an altered expression of vascular endothelial growth factors (VEGF) and pigment epithelium-derived (growth) factor (PEDF) [34,35,36], and with a higher regulation of hypoxia-induced factors [37]. In pathologic myopia, high C3a levels have been described in the plasma of patients with choroid angiogenesis compared to normal controls, which suggests an interaction between innate immunity and choroid angiogenesis [35,38]. Recent studies also describe how C3a acts by stimulating VEGF synthesis at the same time as PEDF synthesis lowers, which promotes the appearance of neovascularization [35].
The aqueous humor analysis is a very useful tool for not only studying the molecular mechanisms involved in axial lengthening, which is necessary for myopia progression, but also for understanding the complement’s role in HM because this would lead to new therapeutic strategies being developed [39,40]. In our article, we correlated the Factor H levels in aqueous humor with central myopia chorioretinal atrophy. To do so, we classified maculopathy according to fundus characteristics and the central choroid thickness measurement. We excluded all those patients with metabolic diseases that could interfere with the results. Thus, the alterations in FH levels were presumably due to ophthalmological alterations. We demonstrated an association between significantly high CFH levels and HM (Figure 1a) with significance set at p ˂ 0.05. Likewise, CFH correlated inversely with choroid thickness (R = −0.624). In turn, the CFH levels rose as maculopathy progressed, and significantly high levels were observed in those eyes presenting diffuse patchy atrophy, macular atrophy and plus disease versus the eyes classified as normal (Figure 2d). These were the two most notable contributions of our study because, as far as we know, no significant increase in Factor H associated with myopic choroidal atrophy has yet been described. Although our study did not allow us to state that this finding was due to a cause-effect reason, consequence or causal finding, the significantly high CFH levels in the HM group (p ˂ 0.05) could suggest a key role played for CFH in myopic pathology, althought to confirm this fact, it would be necessary to study it more deeply. This finding is surprising because, according to our results, CFH appeared to increase as disease progressed; that is, pigment epithelium atrophy was worse, which is associated with choroidal atrophy. Regarding the degree of choroidal atrophy, it must be considered that the study population was not homogeneous in terms of the age of the groups, the high myopic group had a clearly lower average age. This is because the study group was selected from among the patients who were operated on for cataracts. This fact could bias our results. However, we think that in the worst case it would suppose a positive bias, since at an older age a greater degree of choroidal atrophy is expected as is already described [41]. However, the HM group, being younger, has a greater degree of choroidal atrophy and at the same time greater alteration in the CHM than it would be expected in relation to age.
Lower subfoveal choroid thickness values have been recently associated with the presence of the CFH risk genotype and being more predisposed to chorioretininal pathologies. However, this has been described for populations older than the patients in our HM group, for whom such thinning occurred early [41]. The pigment epithelium is one of the main sources of this factor in eyes, which makes this finding paradoxical. One possible explanation is that this increase in HM is due to its synthesis by other eye structures that produce CFH: sclera, retina, optic nerve and ciliary epithelium [19,20,33]. This increased CFH concentration is spontaneously produced to block the action of Factor C3b by preventing the complement cascade from increasing [19,42].
There is evidence to suggest that oxidative stress exists in myopia, especially in HM [43,44,45]. Complement Factor H has antioxidant effects and regulates caspase-dependent apoptosis in retinal pigment epithelial cells submitted to oxidative stress. CFH also blocks the proinflammatory effects of malondialdehyde, a majority lipid peroxidation product, and protects from oxidative stress in vivo in mice [46,47]. In a recent study, our group evidenced nitrosative stress in the aqueous humor of HM patients. Tyrosine nitration is the only type of post-translational modification to occur in the inflammation and nitrosative stress context [48]. In ARMD, the presence of immunoreactive nitrotyrosine in CFH has been demonstrated, which promotes the secretion of proinflammatory and angiogenic cytokine IL-8 from monocytes stimulated with lipid peroxidation products. These findings clearly suggest that nitrated CFH contributes to ARMD progression [49] because the reduced form of CFH plays a protector role under oxidative/nitrosative stress conditions, and its oxidated form plays a pathological role as an activator of the alternative pathway [50]. Our findings agree with recent studies that have examined the complement’s involvement in geographic ARMD atrophy similarly to choroidal atrophy that develops in HM, and suggest that similar molecular systems might come into play to trigger such common symptoms [15,51].
Another complement factor that has been well-studied in relation to ARMD is Factor D. The role it plays as an activator of the alternative pathway is well-known. ComplementFactor D is one of the factors that activates the alternative pathway by acting directly on convertase C3 [20,21]. Although its pathogeny in ARMD remains unclear, evidence for factor D (FD) in the ARMD pathogeny is as follows: in a model of FD genetic deficiency, mice were unprotected against oxidative stress-mediated photoreceptors degeneration, and increased complement systemic activation, including Factor D, was detected in the serum of ARMD patients versus controls [18]. Our study found no significant differences in the mean complement Factor D concentrations in the HM, LM and control emmetropia groups [18,20], which agrees with the expected results as CFD acts as an activator of the alternative pathway, which is the opposite role to that played by CFH that acts as an inhibitor [52].

5. Conclusions

All the data herein obtained, which need to be subsequently verified, could suggest a key role for CFH in myopic pathology. However, based on available data, it is true that we cannot specify if the increases herein found could be due to a cause or a causality of myopic pathology. Further studies involving more patients will be necessary to deepen our understanding of the mechanisms behind this process. In any case, discovering how complement factors are involved in HM can lead to new therapeutic targets to address the development of more efficient pharmacological treatments [13,15,37,43,53,54,55,56].

Author Contributions

Conceptualization, S.M., A.N. and F.B.-M.; methodology, E.G.-G., S.M., C.D., A.N., R.A.-M., M.P. and F.B.-M.; formal analysis, E.G.-G., S.M. and F.B.-M.; investigation, E.G.-G., M.P., C.D., S.M., A.N. and F.B.-M.; resources, A.N., C.D. and F.B.-M.; writing—original draft preparation, E.G.-G., S.M., A.N. and F.B.-M.; writing—review and editing, E.G.-G., S.M., A.N. and F.B.-M.; supervision, S.M., A.N. and F.B.-M.; project administration, F.B.-M.; funding acquisition, F.B.-M. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by funds from the Generalitat Valenciana (AICO 2020/310).

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Curtin, B.J. Physiologic vs Pathologic Myopia: Genetics vs Environment. Ophthalmology 1979, 86, 681–691. [Google Scholar] [CrossRef]
  2. Ohno-Matsui, K.; Lai, T.Y.Y.; Lai, C.-C.; Cheung, C.M.G. Updates of pathologic myopia. Prog. Retin. Eye Res. 2016, 52, 156–187. [Google Scholar] [CrossRef] [PubMed]
  3. Galvis, V.; Tello, A.; Camacho, P.A.; Parra, M.M.; Merayo-Lloves, J. Bio-environmental factors associated with myopia: An updated review. Arch. Soc. Esp. Oftalmol. 2017, 92, 307–325. [Google Scholar] [CrossRef] [PubMed]
  4. Holden, B.A.; Fricke, T.R.; Wilson, D.A.; Jong, M.; Naidoo, K.S.; Sankaridurg, P.; Wong, T.Y.; Naduvilath, T.; Resnikoff, S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology 2016, 123, 1036–1042. [Google Scholar] [CrossRef] [Green Version]
  5. Vongphanit, J.; Mitchell, P.; Wang, J.J. Prevalence and progression of myopic retinopathy in an older population. Ophthalmology 2002, 109, 704–711. [Google Scholar] [CrossRef]
  6. Morgan, I.G.; French, A.N.; Ashby, R.S.; Guo, X.; Ding, X.; He, M.; Rose, K.A. The epidemics of myopia: Aetiology and prevention. Prog. Retin. Eye Res. 2018, 62, 134–149. [Google Scholar] [CrossRef] [Green Version]
  7. Points, K. Updates on Myopia. Updates Myopia 2020, 27–51. [Google Scholar] [CrossRef] [Green Version]
  8. Ohno-Matsui, K. Pathologic myopia. Asia Pac. J. Ophthalmol. 2016, 6, 415–423. [Google Scholar] [CrossRef] [PubMed]
  9. Hayashi, K.; Ohno-Matsui, K.; Shimada, N.; Moriyama, M.; Kojima, A.; Hayashi, W.; Yasuzumi, K.; Nagaoka, N.; Saka, N.; Yoshida, T.; et al. Long-term Pattern of Progression of Myopic Maculopathy: A Natural History Study. Ophthalmology 2010, 117, 1595–1611. [Google Scholar] [CrossRef]
  10. Ohno-Matsui, K.; Jonas, J.B. Posterior staphyloma in pathologic myopia. Prog. Retin. Eye Res. 2018, 70, 99–109. [Google Scholar] [CrossRef]
  11. Hsiang, H.W.; Ohno-Matsui, K.; Shimada, N.; Hayashi, K.; Moriyama, M.; Yoshida, T.; Tokoro, T.; Mochizuki, M. Clinical Characteristics of Posterior Staphyloma in Eyes with Pathologic Myopia. Am. J. Ophthalmol. 2008, 146, 102–110. [Google Scholar] [CrossRef]
  12. Landowski, M.; Kelly, U.; Klingeborn, M.; Groelle, M.; Ding, J.D.; Grigsby, D.; Rickman, C.B. Human complement factor H Y402H polymorphism causes an age-related macular degeneration phenotype and lipoprotein dysregulation in mice. Proc. Natl. Acad. Sci. USA 2019, 116, 3703–3711. [Google Scholar] [CrossRef] [Green Version]
  13. Hageman, G.S.; Anderson, D.H.; Johnson, L.V.; Hancox, L.S.; Taiber, A.J.; Hardisty, L.I.; Hageman, J.L.; Stockman, H.A.; Borchardt, J.D.; Gehrs, K.M.; et al. A Common Haplotype in the Complement Regulatory Gene Factor H (HF1CFH) Predisposes Individuals to Age-Related Macular Degeneration. Proc. Natl. Acad. Sci. USA 2005, 102, 7227–7232. [Google Scholar] [CrossRef] [Green Version]
  14. Edwards, A.O.; Ritter, R.; Abel, K.J.; Manning, A.; Panhuysen, C.; Farrer, L.A. Complement Factor H Polymorphism and Age-Related Macular Degeneration. Science 2005, 308, 421–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Klein, R.J.; Zeiss, C.; Chew, E.Y.; Tsai, J.Y.; Sackler, R.S.; Haynes, C.; Henning, A.K.; Sangiovanni, J.P.; Mane, S.M.; Mayne, S.T.; et al. Complement Factor H Polymorphism in Age-Related Macular Degeneration. Science 2014, 385. [Google Scholar] [CrossRef]
  16. Clark, S.J.; Bishop, P.N.; Day, A.J. Complement factor H and age-related macular degeneration: The role of glycosaminoglycan recognition in disease pathology. Biochem. Soc. Trans. 2010. [Google Scholar] [CrossRef] [Green Version]
  17. Postel, E.A.; Agarwal, A.; Caldwell, J.; Gallins, P.; Toth, C.; Schmidt, S.; Scott, W.K.; Hauser, M.; Haines, J.L.; Pericakvance, M.; et al. Complement Factor H Increases Risk for Atrophic Age-Related Macular Degeneration. Ophthalmology 2006, 113, 1504–1507. [Google Scholar] [CrossRef] [PubMed]
  18. McHarg, S.; Clark, S.J.; Day, A.J.; Bishop, P.N. Age-related macular degeneration and the role of the complement system. Mol. Immunol. 2015. [Google Scholar] [CrossRef]
  19. Rodríguez De Córdoba, S.; Esparza-Gordillo, J.; Goicoechea De Jorge, E.; Lopez-Trascasa, M.; Sánchez-Corral, P. The human complement factor H: Functional roles, genetic variations and disease associations. Mol. Immunol. 2004, 41, 355–367. [Google Scholar] [CrossRef]
  20. Sarma, J.V.; Ward, P.A. The Compliment System. NIH Public Access Author Manuscr. 2012, 343, 227–235. [Google Scholar] [CrossRef]
  21. Hajishengallis, G.; Reis, E.S.; Mastellos, D.C.; Ricklin, D.; Lambris, J.D. Novel mechanisms and functions of complement. Nat. Immunol. 2017, 18, 1288–1298. [Google Scholar] [CrossRef]
  22. Toomey, C.B.; Johnson, L.V.; Bowes Rickman, C. Complement factor H in AMD: Bridging genetic associations and pathobiology. Prog. Retin. Eye Res. 2018, 62. [Google Scholar] [CrossRef]
  23. Amedo, A.O.; Norton, T.T. Visual guidance of recovery from lens-induced myopia in tree shrews (Tupaia glis belangeri). Ophthalmic Physiol. Opt. 2012, 32, 89–99. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Long, Q.; Chen, D.; Chu, R. Illumination with monochromatic long-wavelength light promotes myopic shift and ocular elongation in newborn pigmented guinea pigs. Cutan. Ocul. Toxicol. 2009, 28, 176–180. [Google Scholar] [CrossRef]
  25. Gao, T.T.; Long, Q.; Yang, X. Complement factors C1q, C3 and C5b-9 in the posterior sclera of guinea pigs with negative lens-defocused myopia. Int. J. Ophthalmol. 2015, 8, 675–680. [Google Scholar] [CrossRef] [PubMed]
  26. Lin, H.J.; Wei, C.C.; Chang, C.Y.; Chen, T.H.; Hsu, Y.A.; Hsieh, Y.C.; Chen, H.-J.; Wan, L. Role of Chronic Inflammation in Myopia Progression: Clinical Evidence and Experimental Validation. EBioMedicine 2016, 10, 269–281. [Google Scholar] [CrossRef] [Green Version]
  27. Ikeda, S.; Kurihara, T.; Toda, M.; Jiang, X. Oral Bovine Milk Lactoferrin Administration Suppressed Myopia Development through Matrix Metalloproteinase 2 in a Mouse Model, 1–9. Nutrients 2020, 12, 3744. [Google Scholar] [CrossRef]
  28. Sorsby, A.; Leary, G.A.; Richards, M.J. Correlation ametropia and component ametropia. Vis. Res. 1962, 2, 309–313. [Google Scholar] [CrossRef]
  29. Hosoda, Y.; Yoshikawa, M.; Miyake, M.; Tabara, Y.; Shimada, N.; Zhao, W.; Oishi, A.; Nakanishi, H.; Hata, M.; Akagi, T.; et al. CCDC102B confers risk of low vision and blindness in high myopia. Nat. Commun. 2018, 9, 1782. [Google Scholar] [CrossRef] [Green Version]
  30. Flitcroft, D.I.; He, M.; Jonas, J.B.; Jong, M.; Naidoo, K.; Ohno-Matsui-Matsui, K.; Rahi, J.; Resnikoff, S.; Vitale, S.; Yannuzzi, L. IMI-Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies. Investig. Ophthalmol. Vis. Sci. 2019, 60, M20–M30, PMCID: PMC6735818. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Haines, J.L.; Hauser, M.A.; Schmidt, S.; Scott, W.K.; Olson, L.M.; Gallins, P.; Spencer, K.L.; Kwan, S.Y.; Noureddine, M.; Gilbert, J.R.; et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005, 308, 419–421. [Google Scholar] [CrossRef] [Green Version]
  32. Fisher, D.E.; Klein, B.E.K.; Wong, T.Y.; Rotter, J.I.; Li, X.; Shrager, S.; Burke, G.L.; Klein, R.; Cotch, M.F. Incidence of Age-Related Macular Degeneration in a Multi-Ethnic United States Population the Multi-Ethnic Study of Atherosclerosis. Ophthalmology 2016. [Google Scholar] [CrossRef] [PubMed]
  33. Mandal, M.N.A.; Ayyagari, R. Complement factor H: Spatial and temporal expression and localization in the eye. Investig. Ophthalmol. Vis. Sci. 2006, 47, 4091–4097. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Minkevich, N.I.; Morozova-Roche, L.A.; Iomdina, E.N.; Rakitina, T.V.; Bogachuk, A.P.; Kakuev, D.L.; Smirnova, E.V.; Babichenko, I.I.; Lipkin, V.M. Abnormal pigment epithelium-derived factor processing in progressive myopia. Exp. Eye Res. 2016, 152, 1–9. [Google Scholar] [CrossRef]
  35. Long, Q.; Cao, X.; Bian, A.; Li, Y. C3a Increases VEGF and Decreases PEDF mRNA Levels in Human Retinal Pigment Epithelial Cells. BioMed Res. Int. 2016, 2016. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Chen, W.; Guan, Y.; He, G.; Li, Z.; Song, H.; Xie, S.; Han, Q. Aqueous Levels of Pigment Epithelium-Derived Factor and Macular Choroidal Thickness in High Myopia. J. Ophthalmol. 2015, 2015. [Google Scholar] [CrossRef]
  37. Wu, H.; Chen, W.; Zhao, F.; Zhou, Q.; Reinach, P.S.; Deng, L.; Ma, L.; Luo, S.; Srinivasalu, N.; Pan, M.; et al. Scleral hypoxia is a target for myopia control. Proc. Natl. Acad. Sci. USA 2018, 115, E7091–E7100. [Google Scholar] [CrossRef] [Green Version]
  38. Riddell, N.; Crewther, S.G. Novel evidence for complement system activation in chick myopia and hyperopia models: A meta-analysis of transcriptome datasets. Sci. Rep. 2017, 7, 9719. [Google Scholar] [CrossRef] [Green Version]
  39. Ji, Y.; Rao, J.; Rong, X.; Lou, S.; Zheng, Z.; Lu, Y. Metabolic characterization of human aqueous humor in relation to high myopia. Exp. Eye Res. 2017, 159, 147–155. [Google Scholar] [CrossRef]
  40. Ji, Y.; Rong, X.; Lu, Y. Metabolic characterization of human aqueous humor in the cataract progression after pars plana vitrectomy. BMC Ophthalmol. 2018, 18, 63. [Google Scholar] [CrossRef]
  41. Ryoo, N.K.; Ahn, S.J.; Park, K.H.; Ahn, J.; Seo, J.; Han, J.W.; Kim, K.W.; Woo, S.J. Thickness of retina and choroid in the elderly population and its association with Complement Factor H polymorphism: KLoSHA Eye study. PLoS ONE 2018, 13, e0209276. [Google Scholar] [CrossRef] [PubMed]
  42. Shahulhameed, S.; Vishwakarma, S.; Chhablani, J.; Tyagi, M.; Pappuru, R.R.; Jakati, S.; Chakrabarti, S.; Kaur, I. A Systematic Investigation on Complement Pathway Activation in Diabetic Retinopathy. Front. Immunol. 2020, 11, 154. [Google Scholar] [CrossRef] [Green Version]
  43. Francisco, B.M.; Salvador, M.; Amparo, N. Oxidative stress in myopia. Oxidative Med. Cell. Longev. 2015. [Google Scholar] [CrossRef] [Green Version]
  44. Bosch-Morell, F.; Sanz, A.; Díaz-Llopis, M.; Romero, F.J. Lipid peroxidation products in human subretinal fluid. Free Radic. Biol. Med. 1996, 20, 899–903. [Google Scholar] [CrossRef]
  45. Kim, E.B.; Kim, H.K.; Hyon, J.Y.; Wee, W.R.; Shin, Y.J. Oxidative Stress Levels in Aqueous Humor from High Myopic Patients. Korean J. Ophthalmol. KJO 2016, 30, 172–179. [Google Scholar] [CrossRef] [Green Version]
  46. Borras, C.; Canonica, J.; Jorieux, S.; Abache, T.; El Sanharawi, M.; Klein, C.; Delaunay, K.; Jonet, L.; Salvodelli, M.; Naud, M.-C.; et al. CFH exerts anti-oxidant effects on retinal pigment epithelial cells independently from protecting against membrane attack complex. Sci. Rep. 2019, 9, 13873. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Weismann, D.; Hartvigsen, K.; Lauer, N.; Bennett, K.L.; Scholl, H.P.N.; Issa, P.C.; Cano, M.; Brandstätter, H.; Tsimikas, S.; Skerka, C.; et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 2011, 478, 76–81. [Google Scholar] [CrossRef] [Green Version]
  48. Mérida, S.; Villar, V.M.; Navea, A.; Desco, C.; Sancho-tello, M.; Peris, C.; Bosch-morell, F. Imbalance Between Oxidative Stress and Growth Factors in Human High Myopia. Front. Physiol. 2020, 11, 1–10. [Google Scholar] [CrossRef] [PubMed]
  49. Krilis, M.; Qi, M.; Madigan, M.C.; Wong, J.W.H.; Abdelatti, M.; Guymer, R.H.; Whitelock, J.; McCluskey, P.; Zhang, P.; Qi, J.; et al. Nitration of tyrosines in complement factor H domains alters its immunological activity and mediates a pathogenic role in age related macular degeneration. Oncotarget 2017, 8, 49016–49032. [Google Scholar] [CrossRef] [Green Version]
  50. Krilis, M.; Qi, M.; Qi, J.; Wong, J.W.H.; Guymer, R.; Liew, G.; Hunyor, A.P.; Madigan, M.; McCluskey, P.; Weaver, J.; et al. Dual roles of different redox forms of complement factor H in protecting against age related macular degeneration. Free Radic. Biol. Med. 2018, 129, 237–246. [Google Scholar] [CrossRef] [PubMed]
  51. Conley, Y.P.; Jakobsdottir, J.; Mah, T.; Weeks, D.E.; Klein, R.; Kuller, L.; Ferrell, R.E.; Gorin, M.B. CFH, ELOVL4, PLEKHA1 and LOC387715 genes and susceptibility to age-related maculopathy: AREDS and CHS cohorts and meta-analyses. Hum. Mol. Genet. 2006, 15, 3206–3218. [Google Scholar] [CrossRef]
  52. Stanton, C.M.; Yates, J.R.W.; den Hollander, A.I.; Seddon, J.M.; Swaroop, A.; Stambolian, D.; Fauser, S.; Hoyng, C.; Yu, Y.; Atsuhiro, K.; et al. Complement factor D in age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2011, 52, 8828–8834. [Google Scholar] [CrossRef]
  53. Kanan, Y.; Siefert, J.C.; Kinter, M.; Al-Ubaidi, M.R. Complement factor H, vitronectin, and opticin are tyrosine-sulfated proteins of the retinal pigment epithelium. PLoS ONE 2014, 9, e105409. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Krishna Vadlapatla, R.; Dutt Vadlapudi, A.; Mitra, A.K. Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases HHS Public Access. Curr. Drug Targets 2013, 14, 919–935. [Google Scholar] [CrossRef] [PubMed]
  55. Fan, X.; Heijnen, C.J.; van der Kooij, M.A.; Groenendaal, F.; van Bel, F. The role and regulation of hypoxia-inducible factor-1α expression in brain development and neonatal hypoxic–ischemic brain injury. Brain Res. Rev. 2009, 62, 99–108. [Google Scholar] [CrossRef]
  56. Kurihara, T.; Westenskow, P.D.; Friedlander, M. Hypoxia-inducible factor (HIF)/vascular endothelial growth factor (VEGF) signaling in the retina. Adv. Exp. Med. Biol. 2014. [Google Scholar] [CrossRef]
Jcm 10 02600 g001 550
Figure 1. (a) The mean concentrations of complement Factor H. Values are expressed as mean ± SD. The difference in means (*) was established at a significance of p ˂ 0.05; (b) the mean complement Factor D concentrations; (c) the correlation analysis between eyeball axial length and the measured complement Factor H concentrations; (d) inverse correlation between eyeball axial length and choroid thickness measured by OCT.
Figure 1. (a) The mean concentrations of complement Factor H. Values are expressed as mean ± SD. The difference in means (*) was established at a significance of p ˂ 0.05; (b) the mean complement Factor D concentrations; (c) the correlation analysis between eyeball axial length and the measured complement Factor H concentrations; (d) inverse correlation between eyeball axial length and choroid thickness measured by OCT.
Jcm 10 02600 g001
Jcm 10 02600 g002 550
Figure 2. (a) The mean concentrations of choroidal thickness in each maculopathy. Values are expressed as mean ± SD; (b) Evolution of axial length and degree of maculopathy; (c) inverse between complement Factor H and choroid thickness measured by OCT (R= −0.624, p < 0.05); (d) mean values of correlation complement Factor H and degree of maculopathy. The difference in means (*) was established with a significance of p ˂ 0.05.
Figure 2. (a) The mean concentrations of choroidal thickness in each maculopathy. Values are expressed as mean ± SD; (b) Evolution of axial length and degree of maculopathy; (c) inverse between complement Factor H and choroid thickness measured by OCT (R= −0.624, p < 0.05); (d) mean values of correlation complement Factor H and degree of maculopathy. The difference in means (*) was established with a significance of p ˂ 0.05.
Jcm 10 02600 g002
Table
Table 1. Clinical characteristics of the 122 studied patients. Patients’ ethnicity was Caucasian. Groups were distributed as HM, LM and control for emmetropia according to axial length. Each value represents the mean ± SD, * p ˂ 0.05HM vs. Control group; # p ˂ 0.05 LM vs. Control group.
Table 1. Clinical characteristics of the 122 studied patients. Patients’ ethnicity was Caucasian. Groups were distributed as HM, LM and control for emmetropia according to axial length. Each value represents the mean ± SD, * p ˂ 0.05HM vs. Control group; # p ˂ 0.05 LM vs. Control group.
NAGE
(years)		SPHERICAL EQUIVALENTBCVAAXIAL LENGTH (mm)CHOROID THICKNESS (μm)
CONTROL4375.6 ± 6.9−1.13 ± 1.550.35 ± 0.1822.6 ± 0.4237.1 ± 64.0
LM4773.4 ± 10.3−3.4 ± 3.030.44 ± 0.3724.1 ± 0.6 #199.2 ± 78.0
HM3266.4 ± 12.5−9.69 ± 7.620.61 ± 0.5328.1 ± 1.9 *128.4 ± 101.3 *
Table
Table 2. Distribution of maculopathies in the eyes of the studied patients following IMI’s classification expressed as % of the entire study population.
Table 2. Distribution of maculopathies in the eyes of the studied patients following IMI’s classification expressed as % of the entire study population.
DEGREES OF MACULOPATHYCONTROLLMHM
Normal aspect20.4917.210
TessellatED FUNDUS001.63
dIFFUSE CHORIORETINAL ATROPHY3.278.196.55
PATCHY ATROPHY3.2713.113.27
MACULAR ATROPHY00.0113.11
PLUS: NEOVASCULARIZATION/FUCHS
PLUS: LACQUER CRAKS		0.01012.29
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

García-Gen, E.; Penadés, M.; Mérida, S.; Desco, C.; Araujo-Miranda, R.; Navea, A.; Bosch-Morell, F. High Myopia and the Complement System: Factor H in Myopic Maculopathy. J. Clin. Med. 2021, 10, 2600. https://doi.org/10.3390/jcm10122600

AMA Style

García-Gen E, Penadés M, Mérida S, Desco C, Araujo-Miranda R, Navea A, Bosch-Morell F. High Myopia and the Complement System: Factor H in Myopic Maculopathy. Journal of Clinical Medicine. 2021; 10(12):2600. https://doi.org/10.3390/jcm10122600

Chicago/Turabian Style

García-Gen, Enrique, Mariola Penadés, Salvador Mérida, Carmen Desco, Rafael Araujo-Miranda, Amparo Navea, and F. Bosch-Morell. 2021. "High Myopia and the Complement System: Factor H in Myopic Maculopathy" Journal of Clinical Medicine 10, no. 12: 2600. https://doi.org/10.3390/jcm10122600

APA Style

García-Gen, E., Penadés, M., Mérida, S., Desco, C., Araujo-Miranda, R., Navea, A., & Bosch-Morell, F. (2021). High Myopia and the Complement System: Factor H in Myopic Maculopathy. Journal of Clinical Medicine, 10(12), 2600. https://doi.org/10.3390/jcm10122600

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop